Anti-tuberculosis combination therapy

This page covers all Anti-tuberculosis combination therapy drugs tracked by Drug Landscape: marketed products and active clinical-stage compounds, targeting Multiple: DNA gyrase (moxifloxacin), mycobacterial cell wall synthesis (isoniazid, ethambutol), RNA polymerase (rifampicin), bacterial metabolism (pyrazinamide), Multiple: mycolic acid synthesis (INH), bacterial RNA polymerase (Rifampicin), arabinosyl transferases (Ethambutol), bacterial energy metabolism (Pyrazinamide).

Targets

Multiple: DNA gyrase (moxifloxacin), mycobacterial cell wall synthesis (isoniazid, ethambutol), RNA polymerase (rifampicin), bacterial metabolism (pyrazinamide) · Multiple: mycolic acid synthesis (INH), bacterial RNA polymerase (Rifampicin), arabinosyl transferases (Ethambutol), bacterial energy metabolism (Pyrazinamide)

Phase 3 pipeline (2)

• Moxifloxacin, Isoniazid, Rifampicin Pyrazinamide, Ethambutol · Tuberculosis Research Centre, India · Infectious Disease
  This is a fixed-dose combination of five anti-tuberculosis drugs that work synergistically to inhibit bacterial cell wall synthesis and protein production, killing Mycobacterium tuberculosis through multiple mechanisms.
• INH, Rifampicin, Ethambutol and Pyrazinamide · All India Institute of Medical Sciences · Infectious Disease
  This is a fixed-dose combination of four first-line anti-tuberculosis drugs that work synergistically to inhibit bacterial cell wall synthesis and mycolic acid production, killing Mycobacterium tuberculosis.